SAR444200 + atezolizumab

SAR444200 + atezolizumab is an investigational **combination therapy** for advanced solid tumors, comprising SAR444200, a novel anti-glypican-3 (GPC3) T-cell engager antibody, and atezolizumab, a monoclonal antibody checkpoint inhibitor targeting PD-L1. SAR444200 engages T cells to target and kill GPC3-expressing tumor cells, aiming to activate an anti-tumor immune response, while atezolizumab blocks the PD-L1/PD-1 pathway to further enhance T cell-mediated tumor cell killing. The combination is being studied for safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor efficacy in patients with GPC3+ advanced solid tumors, with a focus on hepatocellular carcinoma and other GPC3-expressing cancers.

Other names

SAR444200SAR-444200SAR 444200atezolizumabanti-GPC3 T-cell engageranti-GPC-3 T-cell engageranti-GPC 3 T-cell engageranti-glypican-3 T-cell engageranti-glypican3 T-cell engageranti-glypican 3 T-cell engager